Physician profile
Mohammad J Baba
NPI 1699764811
$1,070.88
in general payments reported to CMS, 2019-2025
23 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.57 · 2020: $62.50 · 2021: $170 · 2022: $213 · 2023: $200 · 2024: $173 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $154.69 | 2021 | |
| Boston Scientific Corporation | $137.98 | 2025 | Emblem Mri S-Icd |
| Myriad Genetic Laboratories, INC. | $124.14 | 2024 | Prolaris |
| Corcept Therapeutics | $91.42 | 2022-2023 | Korlym |
| Janssen Pharmaceuticals, INC | $62.50 | 2020 | |
| Abbvie INC. | $62.39 | 2023-2025 | Avycaz, Synthroid |
| Angiodynamics, INC. | $48.56 | 2024 | Alphavac |
| Mallinckrodt Hospital Products INC. | $46.90 | 2022 | |
| Exelixis INC. | $43.04 | 2025 | |
| Mannkind Corporation | $35.01 | 2023-2025 | Afrezza |
| Janssen Biotech, INC. | $29.02 | 2023 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $24.67 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.32 | 2023 | Strensiq |
| Genentech USA, INC. | $23.57 | 2019 | |
| Glaxosmithkline, LLC. | $21.57 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $21.54 | 2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $20.82 | 2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.61 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.58 | 2022 | |
| Radius Health, INC. | $17.53 | 2023 | Tymlos |
| Electromed, INC. | $15.05 | 2021 | |
| Ibsa Pharma INC. | $14.99 | 2022 | |
| Grifols USA, LLC | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Baba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.